NRG Therapeutics: Funding, Investors & Team (Oct 2026)
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.
NRG Therapeutics has raised $91.2M across 4 funding rounds on record, the most recent a Series B of $67.5M announced in Sep 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NRG Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2025.
NRG Therapeutics Funding Rounds
NRG Therapeutics raised $18.2M in a Series A announced in Nov 2022.
3 months later, an undisclosed round of $500k was announced in Feb 2023.
1.7 years later, an undisclosed round of $5.0M was announced in Oct 2024.
11 months later, a Series B of $67.5M was announced in Sep 2025.
NRG Therapeutics Founders and Leadership Team
Contact details for the NRG Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →NRG Therapeutics Funding Compared to Other Biotechnology Startups
NRG Therapeutics' latest round of $67.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NRG Therapeutics in Biotechnology and Cambridge
Companies Similar to NRG Therapeutics
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
NRG Therapeutics Funding FAQs
What does NRG Therapeutics do?
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industry professionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease.
How much funding has NRG Therapeutics raised?
NRG Therapeutics has raised $91.2M across 4 rounds on record. The most recent is a Series B of $67.5M announced in Sep 2025.
When did NRG Therapeutics last raise funding?
NRG Therapeutics' most recent funding round on record is a Series B of $67.5M, announced in Sep 2025.
Who is the CEO of NRG Therapeutics?
Neil Miller is listed as CEO at NRG Therapeutics.
Where is NRG Therapeutics headquartered?
NRG Therapeutics is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does NRG Therapeutics have?
NRG Therapeutics is in the 11-50 employee band.
How does NRG Therapeutics' funding compare to other Biotechnology startups?
NRG Therapeutics' latest round of $67.5M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's NRG Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NRG Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.